We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Selonterra To Present Alzheimer’s Disease Therapy Program at Biotech Showcase™ 2020

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Selonterra To Present Alzheimer’s Disease Therapy Program at Biotech Showcase™ 2020 "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Selonterra, a biotechnology company with the aim of discovering therapies for neurodegenerative disorders by harnessing human genetics and gene regulatory networks, has announced a presentation at the Biotech Showcase™ 2020 to be held January 13–15 at the Hilton San Francisco Union Square.

Selonterra will be presenting an update on its Alzheimer’s disease (AD) program focused on developing small molecule therapeutics based on its proprietary APOE4 mechanism.

  • Date:     Tuesday, January 14, 2020
  • Time:    11:00 am (PST)
  • Room:   Franciscan D (Ballroom Level)
  • Venue:  Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA

Selonterra aims to exploit novel insights into the genetic causes of AD in order to find new therapeutic approaches to AD. For example, the altered DNA of APOE4, the main genetic determinant of AD, is thought to control the expression of genes in its chromosomal vicinity; this could be a druggable target linked to key AD pathways.